|
|
|
NKTR Dividend History & Description — Nektar Therapeutics
Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, Co. is studying several immuno-oncology drug candidates including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, Co. is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, Co.'s programs include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. to test the combination of NKTR-255. When considering the Nektar Therapeutics stock dividend history, we have taken known splits into account, such that the NKTR dividend history is presented on a split-adjusted ("apples to apples") basis. Nektar Therapeutics dividend history is presented both in graphical/chart form, and as a NKTR dividend history data table along the right-hand column.
|
NKTR Stock Dividend HistoryThe NKTR dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable NKTR historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the NKTR dividend history record. Also see the NKTR stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Hold (1.50 out of 4)
0th percentile
|
|
|